1. Antiviral combination regimens as rescue therapy in immunocompromised hosts with persistent COVID-19.
- Author
-
Antonello, Roberta Maria, Marangoni, Davide, Ducci, Filippo, Barbiero, Anna, Manciulli, Tommaso, Graziani, Lucia, Di Lauria, Nicoletta, Menicacci, Lorenzo, Paci, Lorenzo, Sordi, Benedetta, Zammarchi, Lorenzo, Morettini, Alessandro, Tomassetti, Sara, Rossolini, Gian Maria, Bartoloni, Alessandro, and Spinicci, Michele
- Abstract
AbstractThe management of severe/prolonged SARS-CoV-2 infections in immunocompromised hosts is still challenging. We describe nine patients with hematologic malignancies with a history of unsuccessful SARS-CoV-2 treatment receiving antiviral combination treatment for persistent infection at a tertiary hospital in central Italy (University Hospital of Careggi, Florence). Combination treatments consisted of nirmatrelvir/ritonavir plus molnupiravir (
n = 4), nirmatrelvir/ritonavir plus remdesivir (n = 4) or remdesivir plus molnupiravir (n = 1) for 10 days, in some cases associated with sotrovimab. Combinations were generally well tolerated. One patient obtained viral clearance but died due to the underlying disease. In eight cases, clinical and virological success was confirmed by radiological follow-up. Antivirals combination is likely to become a mainstay in the future management of COVID-19 among immunocompromised patients, but knowledge in this field is still very limited and prospective studies on larger cohorts are urgently warranted. [ABSTRACT FROM AUTHOR]- Published
- 2024
- Full Text
- View/download PDF